Clinical-stage biotech Zura Bio receives "Overweight" and "Outperform" ratings, with target prices of $26.00 and $21.00, as institutional investors increase stakes.
Clinical-stage biotech firm Zura Bio focusing on immune and inflammatory disorders receives "Overweight" ratings from Piper Sandler with a $26.00 target price and Cantor Fitzgerald, while Oppenheimer gives an "Outperform" rating with a $21.00 target price. Zura Bio's stock opened at $3.28, with recent institutional investors including AQR Capital Management and Bank of New York Mellon Corp increasing their stakes. The company is developing medicines in Phase 2 clinical trials, with key experimental drugs like Tibulizumab, ZB-168, and Torudokimab.
August 18, 2024
3 Articles